This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

talazoparib (Talzenna®)

Reference No. 2451

Publication date:

Appraisal information

talazoparib (Talzenna®) 0.25 mg hard capsule
talazoparib (Talzenna®) 1 mg hard capsule

Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, talazoparib (Talzenna®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with germline BRCA1 or 2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy
Statement of Advice (SOA)